+
For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact [email protected].
++
Content Update
February 18, 2025
Potassium-Competitive Acid Blocker for Erosive and Non-Erosive Esophagitis: In November of 2023 the FDA approved vonoprazan for treatment and healing of erosive esophagitis. An additional indication of treatment and healing of heartburn associated with nonerosive esophagitis was added in July of 2024. Vonoprazan is the first potassium-competitive acid blocker (P-CAB) to be approved in the United States. This new class of medication may be an option for patients who cannot tolerate histamine type-2 receptor antagonists (H2RAs) or proton pump inhibitors (PPIs).
++
LEARNING OBJECTIVES
Upon completion of the chapter, the reader will be able to:
Explain the underlying causes of gastroesophageal reflux disease (GERD).
Understand the difference between typical, atypical, and alarm symptoms.
Determine when diagnostic tests should be recommended based on the clinical presentation.
Identify the desired therapeutic outcomes for patients with GERD.
Recommend appropriate nonpharmacologic and pharmacologic interventions for patients with GERD.
Educate patients on appropriate lifestyle modifications and drug therapy issues including adherence, adverse effects, and drug interactions.
Formulate a monitoring plan to assess the effectiveness and safety of pharmacotherapy for GERD.
++
Gastroesophageal reflux is the retrograde, effortless movement of stomach contents into the esophagus. When troublesome symptoms or mucosal damage occurs as a result of this process, this is defined as gastroesophageal reflux disease (GERD).1,2 Treatment is usually initiated based on symptom presentation rather than laboratory tests or invasive monitoring and consists of various lifestyle interventions and pharmacotherapy. Lack of response to empiric therapies may require further evaluation to identify potential underlying complicating conditions.1,3
+++
EPIDEMIOLOGY AND ETIOLOGY
++
GERD is one of the most common gastrointestinal diagnoses associated with outpatient clinic visits in the United States. Up to 40% of Americans report intermittent GERD symptoms, with around 20% of the US population reporting at least weekly symptoms.1 GERD symptoms can result in decreased work productivity and morbidity, accounting for approximately 110,000 hospital admissions annually.4 In 2015, the US annual health-care expenditures for gastrointestinal diseases was $135.9 billion, with $18.1 billion from esophageal disorders.5 The incidence of GERD complications such as erosive esophagitis and Barrett esophagus increases with age, especially in Caucasian men over 50 years of age with symptoms for more than 10 years.3,4,6
++
The precise etiology of GERD is difficult to determine in most patients. Increased intra-abdominal pressure or decreased lower esophageal sphincter (LES) tone may allow gastric refluxate to enter the esophagus causing GERD symptoms in some patients. These processes can be transient and are often due to physical activity, food, or medications.
++
Retrograde movement of gastric contents into the esophagus, oral cavity, or ...